Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.
Reid Merryman, MD
Advertisement
Articles by Reid Merryman, MD
Advertisement
Latest Updated Articles
Dr Merryman on the Evolution of MRD Assays in LymphomaSeptember 5th 2024
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
4
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
5